Analysis Determines Cost Effectiveness of Various Treatment Strategies for Multiple Myeloma
In this systematic review, researchers analyzed the cost effectiveness of various treatments and treatment lines for multiple myeloma.
In this systematic review, researchers analyzed the cost effectiveness of various treatments and treatment lines for multiple myeloma.
“Despite a lack of head-to-head trials, there is a perception that irAE profiles are
comparable between agents,” the abstract authors wrote.
More than 15,000 distinct irAEs were found for 13,030 patients.
Liquid biopsy can be used to detect a complex type of driver mutation, called ALK, in patients with NSCLC.
While pembrolizumab was not superior to chemotherapy, survival times were similar, suggesting immunotherapy might offer an alternative to chemotherapy.
Results of the YoungPearl study revealed that patient-reported QoL scores were high for palbociclib plus endocrine therapy.
Results of MONARCH-2 showed a statistically significant and clinically meaningful improvement in overall survival with abemaciclib plus fulvestrant.
Pembrolizumab monotherapy does not improve overall survival (OS) compared with single-agent chemotherapy among women with metastatic triple negative breast cancer (mTNBC).
Active surveillance remains the standard of care for patients at intermediate or high risk of recurrence following nephrectomy.
“In my opinion, these data are practice changing,” said lead study author Solange Peters.